Savara (SVRA) Competitors $2.26 +0.06 (+2.73%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. DYN, NKTR, EWTX, CNTA, ETNB, LQDA, JANX, EVO, SPRY, and OCULShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Dyne Therapeutics (DYN), Nektar Therapeutics (NKTR), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), 89bio (ETNB), Liquidia (LQDA), Janux Therapeutics (JANX), Evotec (EVO), ARS Pharmaceuticals (SPRY), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical preparations" industry. Savara vs. Its Competitors Dyne Therapeutics Nektar Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals 89bio Liquidia Janux Therapeutics Evotec ARS Pharmaceuticals Ocular Therapeutix Savara (NASDAQ:SVRA) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk. Does the media favor SVRA or DYN? In the previous week, Dyne Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 7 mentions for Dyne Therapeutics and 5 mentions for Savara. Dyne Therapeutics' average media sentiment score of 0.89 beat Savara's score of 0.38 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in SVRA or DYN? 87.9% of Savara shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, SVRA or DYN? Savara has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Which has better valuation & earnings, SVRA or DYN? Savara is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSavaraN/AN/A-$54.70M-$0.48-4.71Dyne TherapeuticsN/AN/A-$235.94M-$3.59-4.03 Does the MarketBeat Community favor SVRA or DYN? Savara received 254 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 79.03% of users gave Dyne Therapeutics an outperform vote while only 66.74% of users gave Savara an outperform vote. CompanyUnderperformOutperformSavaraOutperform Votes30366.74% Underperform Votes15133.26% Dyne TherapeuticsOutperform Votes4979.03% Underperform Votes1320.97% Do analysts prefer SVRA or DYN? Savara currently has a consensus price target of $7.17, suggesting a potential upside of 217.11%. Dyne Therapeutics has a consensus price target of $44.93, suggesting a potential upside of 210.71%. Given Savara's higher probable upside, analysts clearly believe Savara is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SVRA or DYN more profitable? Dyne Therapeutics' return on equity of -57.46% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets SavaraN/A -58.89% -46.44% Dyne Therapeutics N/A -57.46%-51.62% SummaryDyne Therapeutics beats Savara on 11 of the 16 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$390.61M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-5.268.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book2.176.597.064.69Net Income-$54.70M$144.20M$3.24B$248.14M7 Day Performance-5.04%3.81%2.56%2.39%1 Month Performance-25.17%11.10%8.75%6.06%1 Year Performance-44.06%3.95%31.30%13.57% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara2.2474 of 5 stars$2.26+2.7%$7.17+217.1%-46.5%$390.61MN/A-5.26N/ADYNDyne Therapeutics2.5376 of 5 stars$14.40-2.0%$45.54+216.2%-52.9%$1.64BN/A-4.04100Analyst ForecastHigh Trading VolumeNKTRNektar Therapeutics4.2344 of 5 stars$8.79-12.0%$4.50-48.8%-49.5%$1.64B$87.25M-10.46220Short Interest ↓High Trading VolumeEWTXEdgewise Therapeutics2.6903 of 5 stars$15.26+0.1%$39.78+160.7%-7.9%$1.60BN/A-10.1760CNTACentessa Pharmaceuticals3.7222 of 5 stars$11.94+0.2%$27.89+133.6%+33.9%$1.59B$15M-7.80200Positive NewsHigh Trading VolumeETNB89bio2.7347 of 5 stars$10.57+3.1%$26.43+150.0%+15.7%$1.54BN/A-3.6340News CoveragePositive NewsAnalyst ForecastAnalyst RevisionLQDALiquidia3.7244 of 5 stars$18.02-0.7%$26.67+48.0%+2.3%$1.54B$14.14M-11.0650Analyst ForecastOptions VolumeJANXJanux Therapeutics2.4136 of 5 stars$25.94-1.0%$95.25+267.2%-39.4%$1.54B$9.34M-22.1730Positive NewsAnalyst RevisionEVOEvotec2.0916 of 5 stars$4.12+1.7%$5.93+44.0%-10.5%$1.46B$788.22M0.004,200Gap DownSPRYARS Pharmaceuticals3.4134 of 5 stars$14.53+0.3%$31.00+113.4%+59.9%$1.43B$97.12M-28.4990Positive NewsAnalyst RevisionOCULOcular Therapeutix3.8397 of 5 stars$8.90-1.3%$16.25+82.6%+75.7%$1.42B$59.65M-6.74230Positive News Related Companies and Tools Related Companies DYN Alternatives NKTR Alternatives EWTX Alternatives CNTA Alternatives ETNB Alternatives LQDA Alternatives JANX Alternatives EVO Alternatives SPRY Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
